tDCS in Post-Acute COVID-19 Patients With SARDs

Launched by UNIVERSITY OF SAO PAULO · May 17, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the use of a technique called transcranial direct current stimulation (tDCS) to help patients who have systemic autoimmune rheumatic diseases (SARDs) and are experiencing lingering symptoms after recovering from COVID-19. Many people with SARDs may suffer from ongoing fatigue, pain, and other discomforts, even after the initial COVID-19 infection has cleared. The goal of this study is to see if tDCS can safely reduce these symptoms in patients with SARDs who are dealing with post-acute COVID-19 syndrome.

To participate in the trial, individuals need to be between the ages of 65 and 74 or 29 and 219, and have a diagnosed autoimmune rheumatic disease like rheumatoid arthritis or lupus, along with symptoms of fatigue or general pain. However, some people may not be eligible if they have certain health conditions, such as cancer, heart issues, or a history of seizures. If you join the study, you can expect to receive tDCS treatment and help researchers learn more about its effects on fatigue and pain in this specific group of patients. This is an important step in finding new ways to support those affected by ongoing COVID-19 symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with well-defined ARDs (rheumatoid arthritis, sclerosis systemic, Sjögren syndrome, spondyloarthritis, systemic lupus erythematosus, systemic vasculitis, and systemic autoimmune myopathies)
• • Fatigue or general pains.
• Exclusion Criteria:
• • Neoplasia, using heart pacemarker, using visceral metalic clips, infections (HIV, HTLV-1, hepatitis), pregnance, previous historical of convulsions or epilepsies